Shanghai Hile Bio-Technology Co EBITDA

What does Shanghai Hile Bio-Technology Co do? Shanghai Hile Bio-Technology Co., Ltd. generates revenue through the manufacturing and sale of veterinary vaccines, including inactivated and live formulations. Key products consist of escherichia coli (K88 and K99) gene modified vaccines for piglets, porcine reproductive and respiratory syndrome vaccines, swine infectious atrophic rhinitis vaccines, and Newcastle disease vaccines, both inactivated and live types. The company primarily serves domestic markets in China, distributing its veterinary solutions to agricultural and livestock sectors. Its product portfolio targets specific animal health needs, focusing on piglets and poultry, with a strong emphasis on inactivated and live vaccine technologies. The firm's revenue streams are derived from the sale of its diverse vaccine range, which includes gene modified, inactivated, and live vaccines designed for livestock protection. Products such as Newcastle disease mild vaccines and infectious bronchitis vaccines are sold in both live and inactivated forms, catering to the needs of Chinese farmers and veterinary professionals. Distribution within China ensures consistent market presence and customer base for these specialized animal health solutions. Shanghai Hile Bio-Technology's business model centers on developing and commercializing veterinary vaccines for pigs and poultry, with a focus on inactivated and live vaccine technologies. The company's product line addresses critical health challenges in livestock, including respiratory diseases and bacterial infections, through targeted vaccine formulations. By concentrating on domestic distribution, the company maintains a direct relationship with Chinese agricultural stakeholders, ensuring steady demand for its specialized veterinary products. Shanghai Hile Bio-Technology Co is one of the most popular companies on Eulerpool.